ATS 2024 Final Program

Click on the session title to view the speakers

SUNDAY • MAY 19

25

9:51 Developing a Machine Learning Algorithm That Analyzes Voice Patterns to Identify Risk of Aspiration 10:03 Prediction of Disease Type and Severity in Interstitial Lung Disease Via Machine Learning Analysis of Exhaled Volatile Organic Compounds 10:15 Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis 10:27 Classification of Patients With Idiopathic Pulmonary Fibrosis According to Blood Biomarker Signatures by Consensus Cluster Analysis: A Multiple Machine Learning Approach 10:39 Combination of Multigene Profiles and Clinical Factors Improves Prediction of Short-term Outcomes in Idiopathic Pulmonary Fibrosis 10:51 In Vivo Assessment of Fibrotic Collagen Orientation Using Polarization-sensitive Endobronchial Optical Coherence Tomography to Predict Progression in Idiopathic Pulmonary Fibrosis 11:03 Identification of Molecular Endotypes With Differential Anti-fibrotic Response in Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multi-center Observational Cohorts A14 BUILDING LEGO(LAND): LESSONS LEARNED FROM LARGE SCALE CLINICAL TRIALS IN PAH 9:15 a.m. - 11:15 a.m. San Diego Convention Center Room 29A-D (Upper Level) Oral Presentations: 9:15 Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH) 9:27 Results of a Planned Analysis of the Effects of Genetic Background on Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) 9:39 HS135, A Novel Activin and GDF Trap, Is Highly Efficacious in Models of Group 1 and Group 2 Pulmonary Hypertension (PH) CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

priority populations. Intervention development that is specifically relevant to populations identifying as from Indigenous, sexual and/or gender minority, and currently or formerly incarcerated backgrounds is particularly limited. This symposium will achieve the following objectives: 1) highlight the unique challenges to rigorous research that takes place in understudied priority populations; 2) understand successful strategies of needs-focused community-partnered research to facilitate partnership with understudied priority populations; and 3) identify the role that community-based participatory research can play in balancing these numerous tensions. 9:15 Needs Assessment and Introduction of Speakers 9:25 A Patient's Perspective 9:30 How to Tailor Smoking-Cessation Interventions to Indigenous Communities 9:45 Fulfilling Unmet Needs for LGBT Patients Experiencing Palliative Illness: Safeguarding End-of-Life Care Equity in Sexual and Gender Minority Communities 10:00 Equitable and Ethical Research for Patients Behind Bars 10:15 Community-Based Participatory Research: Equitable Solutions Generated by Patients Themselves 10:30 Panel Discussion A13 TOWARDS IMPLEMENTATION: NEW BIOMARKERS IN ILD 9:15 a.m. - 11:15 a.m. Marriott Marquis San Diego Marina Grand Ballroom 8-9 (Lobby Level, North Tower) Oral Presentations: 9:15 Blood Transcriptomics Differentiates Fibrotic Hypersensitivity Pneumonitis From Idiopathic Pulmonary Fibrosis 9:27 Lung Ultrasound as a Screening Tool in Rheumatoid Arthritis 9:39 Mass Spectrometry-Based Proteomics to Evaluate the Circulating Proteome in Idiopathic Pulmonary Fibrosis (IPF) CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

ATS 2024 Conference Program • San Diego, CA